
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp has demonstrated strong growth in its high-demand segments, highlighted by double-digit increases in Foot & Ankle and significant growth from its BioBrace product line, which is set for a full release in Q3'25 following its FDA approval. Despite facing supply constraints, the company has shown resilience and positive performance trends, indicating an easing of these challenges. Furthermore, management's conservative revenue guidance suggests a strategic focus on sustained gradual growth, reinforcing confidence in the firm's ongoing top-line turnaround efforts.
Bears say
Conmed Corp has experienced a significant decline in stock value, with shares down approximately 27% year-to-date, indicating ongoing challenges in the company's turnaround efforts. The recent shift in price target from $80 to $68 reflects a valuation based on around 15 times the fiscal year 2025 earnings per share estimate of $4.46, signifying a negative sentiment regarding future profitability. Additionally, capital weakness noted, particularly in international markets, appears to stem from challenging year-over-year comparisons rather than an overall reduction in hospital capital budgets, suggesting persistent competitive pressures and operational hurdles.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares